Condition

Biochemical Recurrent Prostate Cancer

ClinicalTrials.gov condition label

Clinical trials3

Recruiting0

Common interventions4

Lead sponsors shown3

Clinical trials

3 shown

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate CancerNCT04876755 · 2021-05-30

Radium-223 in Biochemically Recurrent Prostate CancerNCT04206319 · 2020-09-22

ACTIVE_NOT_RECRUITING

Isoflavone in Prostate-specific Antigen Recurrent Prostate CancerNCT00596895 · 2003-11-01

Common interventions

18F Sodium FluorideDRUG1 IsoflavoneDIETARY_SUPPLEMENT1 MBM-02DRUG1 Radium-223DRUG1

Leading sponsors

Matrix Biomed, Inc.1 National Cancer Institute (NCI)1 University of Florida1

Trial status mix

ACTIVE_NOT_RECRUITING1

COMPLETED1

UNKNOWN1

Phase mix

PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.